GLP-1 Medications for Weight Loss: Mounjaro vs Ozempic vs Wegovy vs Rybelsus
The rise of GLP-1 weight loss medications such as Mounjaro (Tirzepatide), Ozempic, Wegovy, and Rybelsus has revolutionised medical weight management. Originally developed for type 2 diabetes, these therapies are now helping thousands achieve effective, doctor-supervised weight reduction.
For anyone comparing Mounjaro vs Ozempic or other GLP-1 therapies, it’s vital to understand their benefits, side effects, and how they differ. The following guide for Weight Loss explains how each treatment works and what you should consider before starting.
Understanding GLP-1 and Dual Agonist Medications
Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) mimics a natural GLP-1 hormone that regulates blood sugar and appetite.
Tirzepatide (found in Mounjaro) is a dual GLP-1 and GIP agonist, meaning it acts on two hormonal pathways. This dual mechanism makes Mounjaro one of the most powerful weight-loss options available.
For clinical information, visit the Therapeutic Goods Administration (TGA) GLP-1 overview.
Both medications reduce hunger, improve satiety, and promote sustainable fat loss when paired with healthy eating and physical activity.
Is Rybelsus available in Australia?
Yes. Rybelsus is registered with the TGA and can be dispensed in Australian pharmacies upon presentation of a valid prescription. It is approved for the treatment of type 2 diabetes. Any use for weight management is off-label and is decided by your doctor after a clinical assessment.
How do you take oral semaglutide?
Take it first thing in the morning on an empty stomach with a small sip of plain water, no more than 120ml. Wait at least 30 minutes before eating, drinking anything else, or taking other tablets. Doctors usually start at a low dose and increase it slowly.
Does the PBS cover Rybelsus?
No. Rybelsus is not listed on the PBS for weight management, so patients pay the full private price, which varies by pharmacy and dose. Your telehealth consultation fee is separate from the cost of any medicine and is not affected by PBS status.
Mounjaro (Tirzepatide): Dual-Action Innovation
Mechanism: Targets both GIP and GLP-1 receptors to boost insulin sensitivity and suppress appetite.
Dosage: Weekly injection starting at 2.5 mg, titrated up to 15 mg.
Effectiveness: In SURMOUNT-1 trials, patients lost up to 22 % of body weight over 72 weeks—significantly higher than Semaglutide drugs.
Approval: TGA-approved for diabetes; weight-loss indication under review (off-label use permitted under medical supervision).
For eligible patients, Mounjaro offers faster and greater weight loss than most other GLP-1 medications.
Ozempic and Wegovy: Semaglutide-Based GLP-1 Medications
Ozempic is a weekly Semaglutide injection mainly prescribed for diabetes but widely used off-label for weight management.
Wegovy, a higher-dose version, is specifically approved for obesity and delivers stronger appetite suppression.
Ozempic: 0.25–1 mg weekly; 5–10 % average body-weight loss.
Wegovy: Titrated to 2.4 mg weekly; 10–15 % weight loss in trials.
Both medications are available in Australia, with Ozempic PBS-subsidised for diabetes and Wegovy privately available.
Rybelsus: Oral Semaglutide
For patients who prefer tablets, Rybelsus offers an oral form of Semaglutide. It’s less potent but ideal for those avoiding injections.
Dosage: 3 mg–14 mg daily on an empty stomach.
Effectiveness: 5–7 % weight loss in diabetes patients.
Approval: TGA-approved for diabetes; off-label for weight loss.
Comparing GLP-1 Weight Loss Medications
| Medication | Active Ingredient | Use | Form | Average Weight Loss | Australia Approval |
|---|---|---|---|---|---|
| Mounjaro | Tirzepatide | Diabetes, off-label for weight loss | Weekly injection | 20–22 % | Approved for diabetes |
| Wegovy | Semaglutide | Obesity treatment | Weekly injection | 10–15 % | Approved for weight loss |
| Ozempic | Semaglutide | Diabetes, off-label weight loss | Weekly injection | 5–10 % | Approved for diabetes |
| Rybelsus | Semaglutide | Diabetes | Daily tablet | 5–7 % | Approved for diabetes |
Potential Side Effects of GLP-1 Medications
Common side effects include:
Nausea, bloating, or diarrhoea
Fatigue or headaches
Constipation during dose escalation
Rarely: pancreatitis or gallbladder inflammation
Most symptoms improve over time. Always consult your GP before starting or adjusting any GLP-1 medication.
Which GLP-1 Medication Is Right for You?
Mounjaro offers the strongest overall results for patients with metabolic issues or insulin resistance.
Wegovy is ideal for approved obesity management under clinical supervision.
Ozempic suits diabetic patients seeking moderate weight loss.
Rybelsus provides a convenient, needle-free alternative.
Final Thoughts
GLP-1 weight loss medications—Mounjaro, Wegovy, Ozempic, and Rybelsus—represent a major advancement in medical weight management. Choosing the right option depends on your goals, health background, and affordability.
Speak with your GP or Nurse Practitioner to determine which treatment suits you best.
For more scientific insight, explore the TGA’s GLP-1 resource for official Australian guidance.
Thinking about a medically supervised weight loss program? Complete our two-minute pre-screening eligibility check to see if a telehealth consultation with an AHPRA-registered GP is right for you.
Frequently Asked Questions
Is Rybelsus available in Australia?
Yes. Rybelsus is registered with the TGA and can be dispensed in Australian pharmacies with a valid prescription. It is approved for type 2 diabetes. Any use for weight management is off-label and is decided by your doctor after a clinical assessment.
Is Rybelsus approved for weight loss in Australia?
Not specifically. Rybelsus is TGA-approved for type 2 diabetes, not for weight loss. Australian doctors can still prescribe it off-label for weight management when they judge it clinically appropriate. This is a legal and common practice.
Which GLP1 is best for weight loss?
There is no single best option for everyone. The right treatment depends on your health history, your goals, whether you prefer a tablet or an injection, and what your doctor considers safe for you. A clinician reviews your situation and recommends a suitable option on a case-by-case basis.
Is oral semaglutide the same as Ozempic?
They share the same active ingredient, semaglutide, but they are different products. Rybelsus is a daily tablet, and Ozempic is a weekly injection. Because a tablet is absorbed differently, oral semaglutide needs strict timing on an empty stomach to work properly.
Is Rybelsus on PBS?
No. Rybelsus is not subsidised on the PBS for weight management, so patients pay the full private price, which varies by pharmacy and dose. Your te